177 related articles for article (PubMed ID: 32658380)
1. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies.
El Kababri M; Benmiloud S; Cherkaoui S; El Houdzi J; Maani K; Ansari N; Khoubila N; Kili A; El Khorassani M; Madani A; Tazi MA; Ahid S; Hessissen L; Quessar A; Harif M; Khattab M; André N
Pediatr Blood Cancer; 2020 Sep; 67(9):e28508. PubMed ID: 32658380
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02.
Traore F; Togo B; Pasquier E; Dembélé A; André N
Indian J Cancer; 2013; 50(3):250-3. PubMed ID: 24061467
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Devadas SK; Banavali S
Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
[TBL] [Abstract][Full Text] [Related]
5. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Pramanik R; Agarwala S; Gupta YK; Thulkar S; Vishnubhatla S; Batra A; Dhawan D; Bakhshi S
JAMA Oncol; 2017 Sep; 3(9):1222-1227. PubMed ID: 28384657
[TBL] [Abstract][Full Text] [Related]
6. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
[TBL] [Abstract][Full Text] [Related]
7. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of a pediatric metronomic 4-drug regimen.
André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
[TBL] [Abstract][Full Text] [Related]
10. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
El Weshi A; Memon M; Raja M; Bazarbashi S; Rahal M; El Foudeh M; Pai C; Allam A; El Hassan I; Ezzat A
Am J Clin Oncol; 2004 Oct; 27(5):529-34. PubMed ID: 15596925
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
[TBL] [Abstract][Full Text] [Related]
12. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group.
Carpenter PA; White L; McCowage GB; Nayanar V; Toogood I; Shaw PJ; Lockwood L; Tiedemann K
Cancer; 1997 Aug; 80(3):489-96. PubMed ID: 9241083
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy in patients with refractory Ewing sarcoma].
Raciborska A; Bilska K; Drabko K; Rogowska E; Chaber R; Pogorzała M; Wyrobek E; Połczyńska K; Rodriguez-Galindo C; Woźniak W
Med Wieku Rozwoj; 2013; 17(2):117-25. PubMed ID: 23988368
[TBL] [Abstract][Full Text] [Related]
14. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
15. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study.
André N; Rome A; Coze C; Padovani L; Pasquier E; Camoin L; Gentet JC
Clin Ther; 2008 Jul; 30(7):1336-40. PubMed ID: 18691994
[TBL] [Abstract][Full Text] [Related]
16. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
17. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
Fousseyni T; Diawara M; Pasquier E; André N
J Pediatr Hematol Oncol; 2011 Jan; 33(1):31-4. PubMed ID: 21164360
[TBL] [Abstract][Full Text] [Related]
18. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
19. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Loss JF; Santos PP; Leone LD; Brunetto AL
Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
